優良臨床試驗中心

組長   張義芳 醫師

研究人員

黃拓宇 博士
黃文俞、朱洧樂、陳嘉文

進駐研究醫師：林建鴻、陳功深、蘇穎文、蘇迺文、張育誠、江翊豪、宋孟達

支援醫檢師： 細胞與再生醫療中心 周宛蓉

優良臨床試驗中心主要著重在癌症治療與血液疾病等方面研究。

癌症研究：
臨床試驗。臨床試驗中，需檢測許多相關項目，以評估臨床試驗之安全性、特異性或成效，為試驗結果提供實證。本實驗室對於院內臨床試驗，進行相關研究項目之檢測。
個人醫學研究，有多項研究結果指出在癌症病人治療用藥時，化療藥物之藥理機轉與基因多型性關係密切，大大影響藥物治療成效，故在病人化療之前，分析相關藥理基因，可提供病人個人用藥參考。
利用次世代定序(NGS)分析病人檢體，探討癌症基因、致病機轉、用藥等多方面研究。
免疫細胞分析：分析病人在接受化療、標靶藥物治療之後，免疫細胞的分子表現及功能差異。
發展CART細胞治療。

血液疾病：
探討臨床血液疾病及用藥。例如在ET/PV病人觀察其BAFF分子表現及機制探討。
建立斑馬魚模式，分析臨床檢體研究基因與血液疾病的關聯性，來進一步探討血液疾病致病機轉及治療。

本實驗室成立於99年4月，已執行多項院內、院外研究計畫及臨床試驗，並發表多篇論文，期能更進一步了解血液疾病及癌症用藥之作用機轉、效益與安全性，在追求治療效果的同時，也保障病人的用藥安全與生活品質。

Lin HC, Saputra F, Audira G, Lai YH, Roldan MJM, Alos HC, Aventurado CA, Vasquez RD, Tsai GJ, Lim KH, Hsiao CD. Investigating potential cardiovascular toxicity of two anti-leukemia drugs of asciminib and ponatinib in zebrafish embryos. International Journal of Molecular Sciences 2022; 23(19):11711(1-17). (SCIE, BIOCHEMISTRY & MOLECULAR BIOLOGY) (IF: 6.208, Ranking: 69/297=23.23%)

Chou SC, Chang YC, Liao CK, Chen TC, Sun KJ, Huang WH, Wu YF. New presentations and exacerbations of immune thrombocytopenia after coronavirus disease 2019 vaccinations: the Taiwan experience. Platelets 2022; 148:340-347. (SCIE, HEMATOLOGY) (IF: 4.236, Ranking: 35/78=44.87%)

Su YW, Huang WY, Lin HC, Liao PN, Lin CY, Lin XY, Huang SH, Chen YT, Wu PS. Silmitasertib, a casein kinase 2 inhibitor, induces massive lipid droplet accumulation and non-apoptotic cell death in head and neck cancer cells. Journal of Oral Pathology & Medicine 2022; 1-10. (SCIE, PATHOLOGY, DENTISTRY, ORAL SURGERY & MEDICINE) (IF: 3.539, Ranking: 27/92=29.35%)

Chang YC, Chiang YH, Hsu K, Chuang CK, Kao CW, Chang YF, Chang MC, Lim KH, Cheng HI, Hsu YN, Chen CG. Activated naive gammadelta T cells accelerate deep molecular response to BCR-ABL inhibitors in patients with chronic myeloid leukemia. Blood Cancer Journal 2021; 11(11):182. (SCIE, ONCOLOGY) (IF: 9.812, Ranking: 34/245=13.9%)

Wang CI, Chang YF, Sie ZL, Ho AS, Chang JS, Peng CL, Cheng CC. Irradiation suppresses IFNγ-Mediated PD-L1 and MCL1 expression in EGFR-positive lung cancer to augment CD8+ T cells cytotoxicity. Cells 2021; 10(10):2515. (SCIE, CELL BIOLOGY) (IF: 7.666, Ranking: 51/194=26.29%)

Lim KH, Wu JN, Huang TY, Jhuang JY, Chang YC, Lin HC, Chiang YH, Su YW, Chen CG, Chang YF, Lin J. Clonal evolution and heterogeneity in advanced systemic mastocytosis revealed by single-cell DNA sequencing. Blood Advances 2021; 5(6):1733-1736. (SCIE, HEMATOLOGY) (IF: 7.647, Ranking: 16/78=20.51%)

Cheng CC, Lin HC, Chiang YW, Chang J, Sie ZL, Yang BL, Lim KH, Peng CL, Ho AS, Chang YF. Nicotine exhausts CD8+ T cells against tumor cells through increasing MiR-629-5p to repress IL2RB-mediated granzyme B expression. Cancer Immunology, Immunotherapy 2021; 70:1351-1364. (SCIE, ONCOLOGY) (IF: 6.63, Ranking: 58/245=23.67%)

Yang CL, Chao YJ, Wang HC, Hou YC, Chen CG, Chang CC, Shan YS. Local ablation of gastric cancer by reconstituted apolipoprotein B lipoparticles carrying epigenetic drugs. Nanomedicine: Nanotechnology, Biology, and Medicine 2021; 37:102450(1-12). (SCIE, MEDICINE, RESEARCH & EXPERIMENTAL) (IF: 6.458, Ranking: 36/139=25.90%)

Lim KH, Chen LC, Hsu K, Chang CC, Chang CY, Kao CW, Chang YF, Chang MC, Chen CG. BAFF-driven NLRP3 inflammasome activation in B cells. Cell Death & Disease 2020; 11(9):820(1-13). (SCIE, CELL BIOLOGY) (IF: 9.705, Ranking: 35/194=18.04%)

Chang MC, Cheng HI, Hsu K, Hsu YN, Kao CW, Chang YF, Lim KH, Chen CG. NKG2A down-regulation by dasatinib enhances natural killer cytotoxicity and accelerates effective treatment responses in patients with chronic myeloid leukemia. Frontiers in Immunology 2019; 9:3152(1-12). (SCIE, IMMUNOLOGY) (IF: 8.786, Ranking: 33/161=20.50%)